These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Statistical analysis for two-stage seamless design with different study endpoints. Chow SC; Lu Q; Tse SK J Biopharm Stat; 2007; 17(6):1163-76. PubMed ID: 18027223 [TBL] [Abstract][Full Text] [Related]
9. Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials. Hung HM; Wang SJ; O'Neill R J Biopharm Stat; 2007; 17(6):1201-10. PubMed ID: 18027226 [TBL] [Abstract][Full Text] [Related]
10. Method of balanced adjustment in testing co-primary endpoints. Kordzakhia G; Siddiqui O; Huque MF Stat Med; 2010 Aug; 29(19):2055-66. PubMed ID: 20683896 [TBL] [Abstract][Full Text] [Related]
12. Design and analysis issues of multiregional clinical trials with different regional primary endpoints. Tsou HH; Tsong Y; Chang WJ; Dong X; Hsiao CF J Biopharm Stat; 2012 Sep; 22(5):1051-9. PubMed ID: 22946949 [TBL] [Abstract][Full Text] [Related]
13. Blinded sample size reestimation with count data: methods and applications in multiple sclerosis. Friede T; Schmidli H Stat Med; 2010 May; 29(10):1145-56. PubMed ID: 20146203 [TBL] [Abstract][Full Text] [Related]
14. Partition testing in dose-response studies with multiple endpoints. Liu Y; Hsu J; Ruberg S Pharm Stat; 2007; 6(3):181-92. PubMed ID: 17654696 [TBL] [Abstract][Full Text] [Related]
15. Adaptive methods: telling "the rest of the story". Emerson SS; Fleming TR J Biopharm Stat; 2010 Nov; 20(6):1150-65. PubMed ID: 21058111 [TBL] [Abstract][Full Text] [Related]
16. Multiplicity and flexibility in clinical trials. Brannath W; Koenig F; Bauer P Pharm Stat; 2007; 6(3):205-16. PubMed ID: 17674349 [TBL] [Abstract][Full Text] [Related]
17. Exact two-stage designs for phase II activity trials with rank-based endpoints. Wilding GE; Shan G; Hutson AD Contemp Clin Trials; 2012 Mar; 33(2):332-41. PubMed ID: 22074983 [TBL] [Abstract][Full Text] [Related]
18. Power and sample size for clinical trials when efficacy is required in multiple endpoints: application to an Alzheimer's treatment trial. Xiong C; Yu K; Gao F; Yan Y; Zhang Z Clin Trials; 2005; 2(5):387-93. PubMed ID: 16317808 [TBL] [Abstract][Full Text] [Related]
19. Bayesian design and analysis of composite endpoints in clinical trials with multiple dependent binary outcomes. Zaslavsky BG Pharm Stat; 2013; 12(4):207-12. PubMed ID: 23625660 [TBL] [Abstract][Full Text] [Related]
20. Statistical considerations for the next generation of clinical trials. Wu W; Shi Q; Sargent DJ Semin Oncol; 2011 Aug; 38(4):598-604. PubMed ID: 21810519 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]